[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 5, 1973

The Coronary Drug ProjectFindings Leading to Discontinuation of the 2.5-mg/day Estrogen Group

JAMA. 1973;226(6):652-657. doi:10.1001/jama.1973.03230060030009
Abstract

As noted in two previous reports from the Coronary Drug Project,1,2 physicians face a difficult dilemma concerning pharmacologic therapy of hyperlipidemia-hyperlipoproteinemia in an attempt to prevent first or recurrent episodes of clinical coronary heart disease. It is known that susceptibility to premature coronary heart disease is directly related to serum levels of cholesterol, and of low-density and very-low-density lipoproteins. It is also known that elevated serum levels of lipids-lipoproteins frequently can be influenced over long periods of time by available drugs. However, answers to key questions about these pharmaceutical agents are lacking. Do they prevent coronary heart disease and prolong life? Are they reasonably safe in long-term usage?

The Coronary Drug Project—a nationwide collaborative study sponsored by the National Heart and Lung Institute—is the most extensive effort ever undertaken to answer these questions with regard to men who have already experienced one or more episodes of myocardial infarction.1-5

×